Literature DB >> 30105922

Clinical Significance of Sarcopenia among Patients with Advanced Oropharyngeal Cancer.

Akina Tamaki1, Nauman F Manzoor1, Eric Babajanian1, Mustafa Ascha2, Rod Rezaee1, Chad A Zender1.   

Abstract

OBJECTIVES: We investigated the prevalence and impact of sarcopenia on disease-free survival (DFS) and overall survival (OS) in advanced oropharyngeal cancer. STUDY
DESIGN: Retrospective study.
SETTING: Single-institution tertiary cancer care center. SUBJECTS AND METHODS: We identified patients with advanced oropharyngeal cancer with pretreatment positron emission tomography-computed tomography scans for image analysis. Data were collected on the following variables: age, sex, smoking and alcohol status, stage (TNM and American Joint Committee on Cancer), human papillomavirus (HPV) status, body mass index (BMI), and treatment modality.
RESULTS: Of 113 patients identified with oropharyngeal cancer, 32 had sarcopenia: these patients were older (63.5 vs 57.6 years, P = .01), were less likely to be male (53.1% vs 76.5%, P = .03), and had a lower mean BMI (24.5 vs 28.4 kg/m2, P = .009). Eighty-five subjects had HPV-positive disease, and they had a higher BMI (28.2 vs 24.2 kg/m2, P = .01) than that of patients without HPV. Twenty-one subjects who were HPV positive had less cancer recurrence (24.7% vs 48.1%, P = .04) than that of their HPV-negative counterparts. Log-rank testing showed no difference in DFS ( P = .06) associated with sarcopenia but a significant difference in OS ( P = .049). There were differences in DFS ( P = .009) and OS ( P = .023) based on HPV status. According to univariable and multivariable models, HPV positivity exhibited improved DFS and OS. Sarcopenia was not statistically significant in survival models; however, it was associated with increased mortality and recurrence.
CONCLUSION: Sarcopenia is a prognostic factor affecting OS independent of HPV status in advanced oropharyngeal cancer.

Entities:  

Keywords:  head and neck cancer; human papillomavirus; oropharyngeal squamous cell carcinoma; sarcopenia

Mesh:

Year:  2018        PMID: 30105922     DOI: 10.1177/0194599818793857

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Bioelectrical impedance analysis as a quantitative measure of sarcopenia in head and neck cancer patients treated with radiotherapy.

Authors:  Aaron J Grossberg; Crosby D Rock; Jared Edwards; Abdallah S R Mohamed; Debra Ruzensky; Angela Currie; Patricia Rosemond; Jack Phan; G Brandon Gunn; Steven J Frank; William H Morrison; Adam S Garden; Clifton D Fuller; David I Rosenthal
Journal:  Radiother Oncol       Date:  2021-03-15       Impact factor: 6.901

2.  What Factors Affect Changes in Body Composition and Swallowing Function in Patients Hospitalized for Oral Cancer Surgery?

Authors:  Yuko Kagifuku; Haruka Tohara; Yoko Wakasugi; Chiaki Susa; Ayako Nakane; Mizue Toyoshima; Koichi Nakakuki; Yuji Kabasawa; Hiroyuki Harada; Shunsuke Minakuchi
Journal:  Clin Interv Aging       Date:  2020-01-06       Impact factor: 4.458

3.  Sarcopenia is associated with blood transfusions in head and neck cancer free flap surgery.

Authors:  Alexander Joseph Jones; Vincent J Campiti; Mohamedkazim Alwani; Leah J Novinger; Brady Jay Tucker; Andrea Bonetto; Jessica A Yesensky; Michael W Sim; Michael G Moore; Avinash V Mantravadi
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-01-31

Review 4.  The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review.

Authors:  Anna Edwards; Teresa Brown; Brett G M Hughes; Judy Bauer
Journal:  Support Care Cancer       Date:  2022-04-27       Impact factor: 3.359

5.  The effectiveness of skeletal muscle evaluation at the third cervical vertebral level for computed tomography-defined sarcopenia assessment in patients with head and neck cancer.

Authors:  Belinda Vangelov; Judith Bauer; Daniel Moses; Robert Smee
Journal:  Head Neck       Date:  2022-02-09       Impact factor: 3.821

6.  Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis.

Authors:  Alexey Surov; Andreas Wienke
Journal:  Ther Adv Med Oncol       Date:  2021-05-13       Impact factor: 8.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.